Related Experiment Video

Updated: Jun 12, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the type I insulin-like growth factor system for breast cancer therapy

Deepali Sachdev1

  • 1Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. sachd003@umn.edu

Current Drug Targets
|June 16, 2010
PubMed

Insights

Targeting the insulin-like growth factor system (IGF) with drugs shows promise for cancer therapy. Optimizing IGF-1 receptor (IGF-1R) and insulin receptor targeting, along with biomarker development, is crucial for effective treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The insulin-like growth factors (IGFs) pathway, mediated by the type I IGF receptor (IGF-1R), plays a critical role in regulating cancer cell proliferation, survival, metabolism, and metastasis.
  • Drugs targeting IGF-1R are under investigation in human clinical trials for cancer therapy, with potential for near-term approval.
  • The closely related insulin receptor is also implicated, suggesting dual targeting may be necessary for maximal therapeutic effect.

Purpose of the Study:

  • To review current drugs targeting IGF-1R in clinical trials for cancer therapy.
  • To discuss optimal strategies for targeting the IGF-1R pathway in cancer treatment.
  • To highlight the need for biomarkers to identify patients with IGF-1R-driven tumors and predict treatment response, with a focus on breast cancer.

Main Methods:

  • Review of preclinical and clinical data on IGF-1R-targeting drugs.
  • Analysis of the role of IGF-1R and insulin receptor in cancer progression.
  • Discussion of biomarker strategies for patient stratification and response monitoring.

Main Results:

  • Several drugs targeting IGF-1R are in various stages of human clinical trials.
  • Dual targeting of IGF-1R and insulin receptor may enhance therapeutic efficacy.
  • Development of predictive and monitoring biomarkers is essential for personalized cancer therapy.

Conclusions:

  • Targeting the IGF-1R pathway represents a promising therapeutic strategy for various cancers, particularly breast cancer.
  • Combination strategies involving IGF-1R and insulin receptor inhibition, supported by robust biomarkers, are key to optimizing cancer treatment outcomes.
  • Further research into biomarker development is critical for successful clinical implementation of IGF-targeting therapies.

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...